Jacobio Pharmaceuticals (1167.HK), a China-based clinical stage biotech company, announced on Thursday that it has dosed the first two patients in the Phase 1/2a clinical trial of SHP2 inhibitor JAB-3312 in combination with PD-1 antibody Pembrolizumab and MEK inhibitor Binimetinib respectively.
This development triggered a USD20m milestone payment from AbbVie. It is the first milestone payment following the initial upfront fee of USD45m at the outset of Jacobio and AbbVie's collaboration.
Both firms signed a licensing agreement in May 2020 to develop and commercialise SHP2 inhibitors, including JAB-3068 and JAB-3312, on a worldwide basis. SHP2 inhibitors (JAB-3068 and JAB-3312) are Jacobio's innovative, in-house, small molecule anti-cancer drug candidates, which are being investigated in clinical trials as either monotherapy or in combination therapy at more than 30 sites globally.
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax